Modality
Fusion Protein
MOA
DLL3 ADC
Target
FGFR
Pathway
Innate Imm
Breast Ca
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
Oct 2022
→ Sep 2030
Phase 1Current
NCT08144517
2,983 pts·Breast Ca
2025-05→TBD·Recruiting
NCT05217696
672 pts·Breast Ca
2022-10→2030-09·Not yet recruiting
3,655 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-144.5y awayInterim· Breast Ca
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Not yet…
P1
Recruit…
Catalysts
Interim
2030-09-14 · 4.5y away
Breast Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08144517 | Phase 1 | Breast Ca | Recruiting | 2983 | PANSS |
| NCT05217696 | Phase 1 | Breast Ca | Not yet recr... | 672 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| ABS-5770 | Absci | Preclinical | FGFR |